As the first biotech firm to hit the public market via an initial public offering in 2007, Molecular Insight Pharmaceuticals Inc. is bringing in about $70 million to fund ongoing development work on its radiotherapeutics in cancer and its upcoming pivotal study of a molecular imaging agent in heart disease. (BioWorld Today)
As the first biotech firm to hit the public market via an initial public offering in 2007, Molecular Insight Pharmaceuticals Inc. is bringing in about $70 million to fund ongoing development work on its radiotherapeutics in cancer and its upcoming pivotal study of a molecular imaging agent in heart disease. (BioWorld Today)
In its second major collaboration involving melanocortin receptors, Palatin Technologies Inc. signed a potential $310 million deal with AstraZeneca plc to develop small-molecule compounds for obesity and other metabolic disorders. (BioWorld Today)
In its second major collaboration involving melanocortin receptors, Palatin Technologies Inc. signed a potential $310 million deal with AstraZeneca plc to develop small-molecule compounds for obesity and other metabolic disorders. (BioWorld Today)
